✦ LIBER ✦

New targets and inhibitors of HBV replication to combat drug resistance

✍ Scribed by Yung-Chi Cheng; Chun-Xiao Ying; Chung-Hang Leung; Ying Li

Book ID: 117769914
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 452 KB
Volume: 34
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(05)80026-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O.075 Evaluation of replication capacity

O.075 Evaluation of replication capacity and cross-resistance of HBV drug resistant mutants

✍ S. Villet; J. Lucifora; M.N. Brunelle; C. Trépo; D. Durantel; F. Zoulim 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Design of HIV Protease Inhibitors Target

Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance

✍ Ghosh, Arun K.; Chapsal, Bruno D.; Weber, Irene T.; Mitsuya, Hiroaki 📂 Article 📅 2008 🏛 American Chemical Society 🌐 English ⚖ 375 KB

Structure-Based Design of Novel HIV-1 Pr

Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance

✍ Ghosh, Arun K.; Sridhar, Perali Ramu; Leshchenko, Sofiya; Hussain, Azhar K.; Li, 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 398 KB

ChemInform Abstract: Design of HIV Prote

ChemInform Abstract: Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance

✍ Arun K. Ghosh; Bruno D. Chapsal; Irene T. Weber; Hiroaki Mitsuya 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 24 KB 👁 2 views

The main Hepatitis B virus (HBV) mutants

The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication

✍ Gaëtan Billioud; Christian Pichoud; Gerhard Puerstinger; Johan Neyts; Fabien Zou 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 423 KB

Drug Resistance in Cancer Cells || Mecha

Drug Resistance in Cancer Cells || Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors

✍ Siddik, Zahid H.; Mehta, Kapil 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 663 KB

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can